Clinical Trial: Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.

U.S., July 10 -- ClinicalTrials.gov registry received information related to the study (NCT07055529) titled 'Comparison of Efficacy and Safety Psoralen Combined With Ultraviolet A (PUVA) Vs Tofacitinib in the Treatment of Generalized Vitiligo.' on June 15.

Brief Summary: This study aims to compare the efficacy and safety of PUVA versus Tofacitinib in the treatment of generalized vitiligo. Given the high prevalence of vitiligo in Pakistan and the significant psychosocial impact on patients, particularly in Peshawar, this study will provide valuable insights into optimal treatment strategies.

Study Start Date: Dec. 01, 2025

Study Type: INTERVENTIONAL

Condition: Vitiligo, Generalized

Intervention: DRUG: Group A recieving PUVA therapy

T...